Previous 10 |
HERZLIYA, ISRAEL / ACCESSWIRE / November 12, 2020 / PainReform Ltd. (NASDAQ:PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, welcomes Dr. Ellen Baron as a member of the Company's Board of Direct...
HERZLIYA, ISRAEL / ACCESSWIRE / November 5, 2020 / PainReform Ltd. (NASDAQ:PRFX) ("PainReform" or the "Company"), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, welcomes Augustine Lawlor as a member of the Company's Board of Direct...
Studies demonstrate unique benefits of PRF-100 beyond analgesic activity PRF-110 addresses potential concerns in the local administration of anesthetic related to wound healing and suture integrity that are commonly involved in surgical procedures HERZLIYA, ISRAEL / ACCESSWIRE / Oct...
HERZLIYA, ISRAEL / ACCESSWIRE / September 29, 2020 / PainReform Ltd. (NASDAQ:PRFX) ("PainReform" or the "Company"), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that following the closing of its initial public off...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week aheadA relatively light earnings and conference calendar in the week ahead doesn't mean a break for investors. The U.S. airlin...
HERZLIYA, ISRAEL / ACCESSWIRE / September 9, 2020 / PainReform Ltd. (NASDAQ:PRFX) ("PainReform" or the "Company"), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the closing on September 3, 2020 of its initial publi...
News, Short Squeeze, Breakout and More Instantly...
PainReform Ltd. Company Name:
PRFX Stock Symbol:
NASDAQ Market:
Reaches 50% e nrollment in the s econd p art of its Phase 3 c linical t rial of PRF-110 in b unionectomy Remains on track to announce top-line data i n Q 3 202 4 TEL AVIV, Israel, May 15, 2024 (GLOBE N...
TEL AVIV, Israel, May 08, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (" PainReform " or the " Company "), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer o...
(NewsDirect) PainReform CEO Ilan Hadar joined Steve Darling from Proactive to discuss the company at the forefront of addressing the opioid crisis in the United States, is developing PRF-110, an innovative post-operative pain treatment designed as an alternative to traditional opioids. PR...